CD8A and metastatic melanoma: A phase I first-in-humans study of 89Zr-IAB22M2C (anti-CD8 minibody) was conducted to evaluate CD8-targeted PET imaging of tumor-infiltrating T cells in 15 patients with metastatic melanoma, non-small cell lung cancer, and hepatocellular carcinoma [108].